These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38233885)

  • 21. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group.
    Giannini EH; Lovell DJ; Silverman ED; Sundel RP; Tague BL; Ruperto N
    J Rheumatol; 1996 May; 23(5):919-24. PubMed ID: 8724309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoglobulin for multifocal motor neuropathy.
    Keddie S; Eftimov F; van den Berg LH; Brassington R; de Haan RJ; van Schaik IN
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD004429. PubMed ID: 35015296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability and safety of the intravenous immunoglobulin octagam
    Wietek S; Svorc D; Debes A; Svae TE
    Hematology; 2018 May; 23(4):242-247. PubMed ID: 29020871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interventions for necrotizing soft tissue infections in adults.
    Hua C; Bosc R; Sbidian E; De Prost N; Hughes C; Jabre P; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2018 May; 5(5):CD011680. PubMed ID: 29851032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial.
    Kamperman RG; Bogaards JA; Evers SW; Walter HAW; de Visser M; de Borgie C; Colen-de Koning JCA; Verhamme C; Maas M; Eftimov F; van Schaik IN; van der Kooi AJ; Raaphorst J
    BMJ Open; 2023 Jul; 13(7):e067435. PubMed ID: 37429682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin for chronic residual peripheral neuropathy in microscopic polyangiitis: A multicentre randomised double-blind trial.
    Arimura Y; Sobue G; Hattori N; Takashima H; Harigai M; Nagata K; Makino H
    Mod Rheumatol; 2023 Nov; 33(6):1125-1136. PubMed ID: 36346309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.
    Dodel R; Rominger A; Bartenstein P; Barkhof F; Blennow K; Förster S; Winter Y; Bach JP; Popp J; Alferink J; Wiltfang J; Buerger K; Otto M; Antuono P; Jacoby M; Richter R; Stevens J; Melamed I; Goldstein J; Haag S; Wietek S; Farlow M; Jessen F
    Lancet Neurol; 2013 Mar; 12(3):233-43. PubMed ID: 23375965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
    Hahn AF; Beydoun SR; Lawson V; ; Oh M; Empson VG; Leibl H; Ngo LY; Gelmont D; Koski CL
    J Peripher Nerv Syst; 2013 Dec; 18(4):321-30. PubMed ID: 24725024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
    Léger JM; Chassande B; Musset L; Meininger V; Bouche P; Baumann N
    Brain; 2001 Jan; 124(Pt 1):145-53. PubMed ID: 11133794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Lancet; 1997 Mar; 349(9052):589-93. PubMed ID: 9057729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
    Dalakas MC
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2009 Jan; (1):CD001797. PubMed ID: 19160200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.